Pure Global

First Line TIP in Poor Prognosis TGCTs. - Trial NCT02414685

Access comprehensive clinical trial information for NCT02414685 through Pure Global AI's free database. This Phase 2 trial is sponsored by National Cancer Institute, Slovakia and is currently Completed. The study focuses on Germ Cell Tumor. Target enrollment is 19 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT02414685
Phase 2
Completed
drug
Trial Details
ClinicalTrials.gov • NCT02414685
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
First Line TIP in Poor Prognosis TGCTs.
A Treatment Strategy of the Use of 1st Line Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Based on Tumor Marker Decline: A Phase II Trial of Paclitaxel, Ifosfamid and Cisplatin Regimen.

Study Focus

Germ Cell Tumor

Paclitaxel

Interventional

drug

Sponsor & Location

National Cancer Institute, Slovakia

Bratislava, Slovakia

Timeline & Enrollment

Phase 2

Apr 01, 2015

Jun 01, 2020

19 participants

Primary Outcome

Complete response rate

Summary

TIP in the 1st line treatment of GCTs patients with unfavorable decline of serum tumor
 markers after 1 cycle of the BEP regimen.TIP will be administered to the patient until
 progression, unacceptable toxicity, complete response or inability of the subject to comply
 with study requirements.

ICD-10 Classifications

Malignant neoplasms
Malignant neoplasm: Jejunum
Malignant neoplasm: Prepuce
Malignant neoplasm: Female genital organ, unspecified
Malignant neoplasm: Vulva, unspecified

Data Source

ClinicalTrials.gov

NCT02414685

Non-Device Trial